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Figure S1
. Activation of 5b in the presence of 4 mM GSH. Liquid chromatography/mass spectrometry (LC/MS) analysis of the reaction mixture after two half-lives. The peak identities from left to right are as follows; PARP inhibitor 6b, arylated GSH (7), and unmetabolized 5b. We have observed a strong and significant correlation between toxicity of compound 2 and levels of OGG1 in NSCLC cells.
Cells expressing very low levels

S3
of OGG1 protein were most sensitive to 2. This appears to be true for NO-releasing PARP inhibitor prodrugs: the lower the OGG1 levels the more toxic 5b was ( Figure S2 ). This is an interesting finding, considering recent reports about a "BRCAness phenotype" that is sensitive to PARP inhibitors. This phenotype was described for triple-negative breast cancers lacking DNAdamage defense, including that associated with BER. 3 It is possible that "BRCAness" is a more general phenomenon, not limited to breast cancers only, and that lacking or low expression of OGG1 plays an important role.
Similarly, levels of peroxiredoxin 1 (PRX1) correlated significantly with toxicity of 5b ( Figure S2 ). We have shown before that low levels of this ROS/RNS scavenger sensitized NSCLC cells to the toxicity of compound 2. . HPLC analysis of the reaction mixtures produced on reacting 5b with 4 mM GSH in the presence or absence of GSTP1. Peak 1 is PARP inhibitor 6b and Peak 2 is arylated GSH (7).
Product distribution was not altered.
